Clinical Trial

A Study to Evaluate the Effect of KarXT on Urological Safety

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to characterize the effect of KarXT on voiding dynamics and urological safety in participants with DSM-5 schizophrenia.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2025-10-24; most recent amendment 2026-06-02.
Status change: Not Yet Recruiting → Recruiting 2026-01-20
Trial Details
NCT Number NCT07221877
Lead Sponsor Bristol-Myers Squibb
Conditions Schizophrenia
Enrollment 60 participants
Start Date 2026-01-20
Primary Completion 2027-12-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-03